Literature DB >> 12133359

[Expression and clinical significance of c-kit oncogene in gastrointestinal stromal tumors].

Xiaohong Liu1, Dalie Ma, Lili Wu, Chenguang Bai, Hongjie Hu.   

Abstract

OBJECTIVE: To investigate the clinicopathological and prognostic significance of the c-kit protein in gastrointestinal stromal tumor (GIST).
METHODS: Paraffin embedded materials from 53 benign GISTs, 13 potentially malignant and 55 malignant cases were analysed for c-kit expression by immunohistochemical method, while using leiomyomas and schwannomas as controls. Positive signals were shown in cytoplasma and cell membrane.
RESULTS: Of 122 GISTs, 118 (97%) were positive for c-kit. Localization of positive signals was accurate. The rate of c-kit protein in benign, potentially malignant and malignant cases was 98% (53/54), 93% (12/13), 96% (53/55) respectively. Compared with benign GIST, the positivity of c-kit in metastasis or recurrent cases decreased, but c-kit protein expression rate was not significantly different between the three patterns of GIST (chi(2) = 1.167, P > 0.05). Leiomyomas and schwannomas were typically c-kit negative.
CONCLUSION: As a sensitive and specific marker of GIST, c-kit seems to be a useful antibody in the diagnosis and differential diagnosis of GIST, but it may not be used as a prognostic index.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133359

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  2 in total

1.  Diagnosis value of CD117 and PDGFRA, alone or in combination DOG1, as biomarkers for gastrointestinal stromal tumors.

Authors:  Chunwei Xu; Hongyan Han; Jingjing Wang; Bo Zhang; Yun Shao; Liying Zhang; Huaitao Wang; Haiyan Wang; Yongfang Wu; Xiaobing Li; Ruiming Li; Yuwang Tian
Journal:  Ann Transl Med       Date:  2015-11

2.  Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor.

Authors:  Feng-Yu Liu; Ji-Ping Qi; Feng-Lin Xu; Ai-Ping Wu
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.